Vernalis plc today announces that CTI BioPharma Corp. (CTI), a US corporation publicly listed on NASDAQ, replaces the UK venture capital backed Chroma Therapeutics (Chroma) as worldwide licensee of tosedostat. CTI previously held rights to tosedostat in the Americas under a Licence Agreement with Chroma. Chroma no longer retains any ongoing rights or financial interest in tosedostat.
Chroma Therapeutics
Breaking News
Subscribe to VCpost newsletter
Most Popular
- Doctors Raise Concerns Over Proposed Capital Gains Tax Changes
- Tesla Shareholder Asks Judge to Prevent Elon Musk From Moving Pay Fight to Texas to Evade Delaware Ruling
- How to Get IRS Unclaimed Tax Refunds: Here's What to Do If You Think You Have Pending Payments
- Celebrity Designer Nancy Gonzalez Jailed for Smuggling Crocodile, Python Handbags
- Kroger and Albertsons to Sell off 166 Stores in Effort to Gain Approval for Their $25 Billion Merger
- Illinois Woman, Who Mysteriously Drowned After Giving $1.5 Million to Online Romance Scammers, Knew She'd 'End up Dead'
- Where's My Child Tax Credit 2024: When to Receive My Money After April 15 Tax Filing Deadline?
- Biden Administration Announces New Federal Rules: Airlines Required to Automatically Give Refunds for Delayed, Canceled Flights
